<SEC-DOCUMENT>0001104659-25-048689.txt : 20250514
<SEC-HEADER>0001104659-25-048689.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514203959
ACCESSION NUMBER:		0001104659-25-048689
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ernexa Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-42217
		FILM NUMBER:		25948095

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(617) 798-6700

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eterna Therapeutics Inc.
		DATE OF NAME CHANGE:	20221017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IAF, LLC
		CENTRAL INDEX KEY:			0001989492
		ORGANIZATION NAME:           	
		EIN:				873482819
		STATE OF INCORPORATION:			SC
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		C/O 115 CHURCH STREET
		CITY:			CHARLESTON
		STATE:			SC
		ZIP:			29401
		BUSINESS PHONE:		843-270-4171

	MAIL ADDRESS:	
		STREET 1:		C/O 115 CHURCH STREET
		CITY:			CHARLESTON
		STATE:			SC
		ZIP:			29401
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-23-127707</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: IAF, LLC -->
          <cik>0001989492</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.005 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000748592</issuerCik>
        <issuerName>Ernexa Therapeutics Inc.</issuerName>
        <issuerCusip>114082209</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>1035 Cambridge Street</com:street1>
          <com:street2>Suite 18A</com:street2>
          <com:city>Cambridge</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02141</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>IAF, LLC</reportingPersonName>
      <citizenshipOrOrganization>SC</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3255421.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3255421.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3255421.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.2</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Row 11 is calculated based on 62,363,763 shares of the Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission on May 7, 2025.

The number of shares beneficially owned in Rows 5, 7 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to the Reporting Person pursuant to that certain Securities Purchase Agreement dated as of March 31, 2025 between the Issuer and the purchasers identified on the signature pages thereto, including the Reporting Person, following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Ernexa Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1035 Cambridge Street Suite 18A Cambridge, MA, 02141</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>IAF, LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>c/o 115 Church Street, Charleston, South Carolina 29401</principalBusinessOfficeOrResidenceAddress>
        <citizenship>SC</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See Row 9 of the Reporting Person's cover page to this Schedule 13G.</amountBeneficiallyOwned>
        <classPercent>See Row 11 of the Reporting Person's cover page to this Schedule 13G.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See Row 5 of the Reporting Person's cover page to this Schedule 13G.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See Row 6 of the Reporting Person's cover page to this Schedule 13G.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See Row 7 of the Reporting Person's cover page to this Schedule 13G.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See Row 8 of the Reporting Person's cover page to this Schedule 13G.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>IAF, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Edward G. R. Bennett</signature>
        <title>Edward G. R. Bennett, Authorized Person</title>
        <date>05/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
